BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 250 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q3 2021. The put-call ratio across all filers is 0.73 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,647,000 | +4.7% | 10,900 | +0.9% | 0.01% | +14.3% |
Q2 2022 | $1,573,000 | +68.1% | 10,800 | +36.7% | 0.01% | +133.3% |
Q1 2022 | $936,000 | -5.6% | 7,900 | +9.7% | 0.00% | 0.0% |
Q4 2021 | $992,000 | -31.3% | 7,200 | -30.8% | 0.00% | -40.0% |
Q3 2021 | $1,444,000 | +180.9% | 10,400 | +96.2% | 0.01% | +150.0% |
Q2 2021 | $514,000 | +242.7% | 5,300 | +140.9% | 0.00% | +100.0% |
Q1 2021 | $150,000 | -64.2% | 2,200 | -55.1% | 0.00% | -50.0% |
Q4 2020 | $419,000 | +46.5% | 4,900 | +11.4% | 0.00% | +100.0% |
Q3 2020 | $286,000 | -32.5% | 4,400 | -24.1% | 0.00% | -50.0% |
Q2 2020 | $424,000 | -47.9% | 5,800 | -68.8% | 0.00% | -50.0% |
Q2 2019 | $814,000 | +65.8% | 18,600 | +2.2% | 0.00% | +100.0% |
Q4 2017 | $491,000 | -27.8% | 18,200 | 0.0% | 0.00% | -33.3% |
Q3 2017 | $680,000 | +844.4% | 18,200 | +527.6% | 0.00% | – |
Q2 2017 | $72,000 | – | 2,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |